<DOC>
	<DOCNO>NCT00389376</DOCNO>
	<brief_summary>The purpose study determine safety tolerability different dosage silymarin subject Hepatitis C Non-Alcoholic Fatty Liver Disease .</brief_summary>
	<brief_title>Phase I Trial Silymarin Chronic Liver Diseases</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<criteria>Inclusion criterion Subjects eligible enrollment study meet follow criterion : Males female ; age least 18 year screen Abnormal ALT &gt; 65 IU/L ( ie , approximately 1.5 x upper limit normal ) Negative urine pregnancy test ( woman childbearing potential ) document within 24hour period prior first dose silymarin . Females childbearing potential must use two reliable form effective contraception study ( drug followup ) Hepatitis C virus ( HCV ) patient Previous treatment interferonbased therapy without sustained virological response . Serum HCV RNA quantifiable level detection assay , within 1 year screen end therapy No antiviral therapy least 6 month prior screen visit Nonalcoholic fatty liver disease ( NAFLD ) patient : Liver biopsy compatible NAFLD within 3 year screen Absence liver diseases serological screening ( antiHCV , HBsAg ) , historical serological data within 3 year screen acceptable . Before enter study , subject must agree consume alcohol 48 hour prior PK sample day study . Exclusion criterion Subjects follow eligible participation : Use silymarin milk thistle preparation within 30 day screen Use antioxidant vitamin E , vitamin C , glutathione , alphatocopherol , within 30 day screen . A multivitamin standard dose allow . Allergy/sensitivity milk thistle preparation Use silymarin antioxidant ( ) screen period . Use warfarin , metronidazole chronic use acetaminophen great two gram per day Previous liver biopsy demonstrate presence cirrhosis Previous liver biopsy demonstrate great equal 15 % steatosis evidence steatohepatitis HCV cohort Positive test antiHIV HBsAg within 3 year screen Positive urine drug screen drug abuse screen Alcohol consumption one drink equivalent ( &gt; 12 gram ) per day . Patients consume past must maintain level 12 gram less per day alcohol consumption least six month prior screen . History chronic liver disease , include metabolic disease , document appropriate test ( ) Women ongoing pregnancy breastfeeding , contemplate pregnancy Platelet count &lt; 130,000 cells/mm3 . Serum creatinine level &gt; 1.5 time upper limit normal screening , CrCl 60 cc/min , currently dialysis . The creatinine clearance ( CrCl ) calculate accord CockcroftGault . Evidence alcohol drug abuse within 6 month prior screen Evidence decompensated liver disease define follow : serum albumin &lt; 3.2 g/dl , total bilirubin &gt; 1.5 mg/dl , PT/INR &gt; 1.3 time normal screening , history presence ascites encephalopathy , bleed esophageal varix History evidence severe illness condition would make patient , opinion investigator , unsuitable study ( poorly control psychiatric disease , coronary artery disease , active gastrointestinal condition might interfere drug absorption ) History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hepatitis , autoimmune hemolytic anemia , severe psoriasis , rheumatoid arthritis ) could affect inflammatory biomarkers History solid organ bone marrow transplantation History thyroid disease poorly control prescribed medication Use oral steroid within 30 day prior screen Concurrent medication CYP3A4 inducer Inability unwillingness provide inform consent abide study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>